Muscular Dystrophy – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Muscular Dystrophy – Pipeline Review, H1 2020’, provides an overview of the Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Muscular Dystrophy

– The report reviews pipeline therapeutics for Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Muscular Dystrophy therapeutics and enlists all their major and minor projects

– The report assesses Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Muscular Dystrophy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Muscular Dystrophy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Muscular Dystrophy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics Inc

AlloMek Therapeutics

Amicus Therapeutics Inc

AMO Pharma Ltd

Anima Biotech Inc

Armgo Pharma Inc

ARTHEx Biotech SL

Asklepios BioPharmaceutical Inc

Audentes Therapeutics Inc

Avidity Biosciences LLC

Benitec Biopharma Ltd

Biophytis SA

Bioprojet SCR

CalyGene Biotechnology Inc

Casma Therapeutics Inc

Catabasis Pharmaceuticals Inc

Constant Therapeutics LLC

Corcept Therapeutics Inc

CRISPR Therapeutics AG

Design Therapeutics Inc

Dyne Therapeutics Inc

Elixirgen Therapeutics LLC

Enzerna Biosciences LLC

Exodos Life Sciences Limited Partnership

Expansion Therapeutics Inc

Facio Therapies BV

Fulcrum Therapeutics Inc

Genea Biocells

Genzyme Corp

Gilead Sciences Inc

Keros Therapeutics Inc

Locana Inc

ML Bio Solutions Inc

Myogem Health Company SL

NeuBase Therapeutics Inc

Nexien Biopharma Inc

Nymirum Inc

Pfizer Inc

Phrixus Pharmaceuticals Inc

Prothelia Inc

Resverlogix Corp

ReveraGen BioPharma Inc

SanBio Inc

Santhera Pharmaceuticals Holding AG

Sarcomed AB

Sarepta Therapeutics Inc

Seelos Therapeutics, Inc.

Siwa Therapeutics Inc

StrideBio Inc

Syros Pharmaceuticals Inc

Tamid Bio Inc

Vertex Pharmaceuticals Inc

Vita Therapeutics Inc

Xonovo Inc

Table of Contents

Table of Contents

Introduction

Muscular Dystrophy - Overview

Muscular Dystrophy - Therapeutics Development

Muscular Dystrophy - Therapeutics Assessment

Muscular Dystrophy - Companies Involved in Therapeutics Development

Muscular Dystrophy - Drug Profiles

Muscular Dystrophy - Dormant Projects

Muscular Dystrophy - Discontinued Products

Muscular Dystrophy - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Muscular Dystrophy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Muscular Dystrophy – Pipeline by Achelios Therapeutics Inc, H1 2020

Muscular Dystrophy – Pipeline by AlloMek Therapeutics, H1 2020

Muscular Dystrophy – Pipeline by Amicus Therapeutics Inc, H1 2020

Muscular Dystrophy – Pipeline by AMO Pharma Ltd, H1 2020

Muscular Dystrophy – Dormant Projects, H1 2020

Muscular Dystrophy – Dormant Projects, H1 2020 (Contd..1), H1 2020

Muscular Dystrophy – Dormant Projects, H1 2020 (Contd..2), H1 2020

Muscular Dystrophy – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Muscular Dystrophy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports